Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06212999 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

Study acronym: STOP-HS LTE
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 74 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. 2 versions Re-verified since Mar 19, 2026, no change to tracked fieldsv73-v74
  2. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 960 to confirmed 617 · Study sites: 171 to 165v72 Show 2 more changesShow less
    • Enrollment target: estimated 960 to confirmed 617
    • Study sites: 171 to 165
  3. Site details revised at 1 of 171 sitesv71
  4. Site details revised at 1 of 171 sitesv70
  5. Site details revised at 2 of 171 sitesv69
Show 44 earlier versionsHide 44 earlier versions
  1. Study sites: 170 to 171v68
  2. Study sites: 172 to 170v67
  3. Site details revised at 2 of 172 sitesv66
  4. Site details revised at 1 of 172 sitesv65
  5. Site details revised at 2 of 172 sitesv64
  6. Site details revised at 2 of 172 sitesv63
  7. Site details revised at 3 of 172 sitesv62
  8. Site details revised at 2 of 172 sitesv61
  9. Site details revised at 1 of 172 sitesv60
  10. Site details revised at 1 of 172 sitesv59
  11. Site details revised at 4 of 172 sitesv58
  12. Site details revised at 2 of 172 sitesv57
  13. Site details revised at 2 of 172 sitesv56
  14. Study sites: 173 to 172v55
  15. Study sites: 171 to 173v54
  16. Study sites revised (171)v53 See this version in full on ClinicalTrials.gov ↗
  17. Site details revised at 6 of 171 sitesv52
  18. Study sites revised (171)v51 See this version in full on ClinicalTrials.gov ↗
  19. Site details revised at 2 of 171 sitesv50
  20. Study sites revised (171)v49 See this version in full on ClinicalTrials.gov ↗
  21. Study sites: 170 to 171v48
  22. Site details revised at 2 of 170 sitesv47
  23. Study sites revised (170)v46 See this version in full on ClinicalTrials.gov ↗
  24. Study sites: 169 to 170v45
  25. Study sites revised (169)v44 See this version in full on ClinicalTrials.gov ↗
  26. Site details revised at 1 of 169 sitesv43
  27. Study sites revised (169)v42 See this version in full on ClinicalTrials.gov ↗
  28. Site details revised at 1 of 169 sitesv41
  29. Study sites: 166 to 169v40
  30. Study sites: 167 to 166v39
  31. Site details revised at 2 of 167 sitesv38
  32. Study sites: 168 to 167v37
  33. Study sites: 169 to 168v36
  34. Site details revised at 4 of 169 sitesv35
  35. Study sites: 167 to 169v34
  36. Study sites: 168 to 167v33
  37. Site details revised at 6 of 168 sitesv32
  38. Site details revised at 5 of 168 sitesv31
  39. Study sites: 172 to 168v30
  40. Site details revised at 1 of 172 sitesv29
  41. Site details revised at 1 of 172 sitesv28
  42. Site details revised at 5 of 172 sitesv27
  43. Site details revised at 8 of 172 sitesv26
  44. Site details revised at 1 of 172 sitesv25
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate long-term safety and efficacy of povorcitinib in participants with moderate to severe hidradenitis suppurativa who completed the 54 weeks of study treatment within the originating parent Phase 3 studies (INCB 54707-301 \[NCT05620823\] or INCB 54707-302 \[NCT05620836\]).
Trial Details
NCT Number NCT06212999
Lead Sponsor Incyte Corporation
Conditions Hidradenitis Suppurativa (HS)
Enrollment 617 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov